

Filippo Schepis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/741333/publications.pdf>

Version: 2024-02-01

70
papers

5,321
citations

136740

32
h-index

114278

63
g-index

74
all docs

74
docs citations

74
times ranked

6563
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of transjugular intrahepatic portosystemic shunt in patients with cirrhosis and ascites: Recent evolution and open questions. <i>Hepatology</i> , 2023, 77, 640-658.	3.6	21
2	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2276-2286.e6.	2.4	42
3	Portosystemic shunt is an effective treatment for complications of portal hypertension in hepatic myeloid metaplasia and improves nutritional status. <i>Liver International</i> , 2022, 42, 419-424.	1.9	4
4	Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: A long-term follow-up study. <i>Annals of Hepatology</i> , 2022, 27, 100683.	0.6	4
5	Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 811-818.	1.8	55
6	Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19. <i>Blood Advances</i> , 2021, 5, 662-673.	2.5	42
7	Relevance of Spontaneous Portosystemic Shunts Detected with CT in Patients with Cirrhosis. <i>Radiology</i> , 2021, 299, 133-140.	3.6	38
8	Controlled underdilation using novel VIATORRÁ® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation. <i>JHEP Reports</i> , 2021, 3, 100264.	2.6	35
9	Proximal Splenic Artery Embolization to Treat Refractory Ascites in a Patient With Cirrhosis. <i>Hepatology</i> , 2021, 74, 3534-3538.	3.6	5
10	Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2021, 53, 1089-1104.	0.4	10
11	Reply to: “The clinical advantage of fixed 8-mm diameter VCX stents over underdilated VTS stents is not established in refractory ascites”. <i>JHEP Reports</i> , 2021, 3, 100349.	2.6	1
12	Effects of sildenafil on right ventricle remodelling in Portopulmonary hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021, 70, 102071.	1.1	11
13	Endoscopic radiofrequency ablation for the treatment of severe gastric antral vascular ectasia in patients with cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1414-1419.	0.8	0
14	Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes. <i>Internal and Emergency Medicine</i> , 2020, 15, 37-48.	1.0	50
15	The use of intrahepatic portosystemic shunt in HIV positive patients: A retrospective multicentric study. <i>Digestive and Liver Disease</i> , 2020, 52, 355-357.	0.4	0
16	Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV. <i>Aids</i> , 2020, 34, 1915-1921.	1.0	11
17	Cardiodynamic state is associated with systemic inflammation and fatal acute-to-chronic liver failure. <i>Liver International</i> , 2020, 40, 1457-1466.	1.9	46
18	Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study. <i>European Journal of Internal Medicine</i> , 2020, 79, 70-75.	1.0	13

#	ARTICLE	IF	CITATIONS
19	Transjugular Intrahepatic Portosystemic Shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: A real-life, case-control study. <i>Digestive and Liver Disease</i> , 2019, 51, 870-874.	0.4	1
20	Angiopoietin-2/Tie2 Inhibition by Regorafenib Associates With Striking Response in a Patient With Aggressive Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 70, 745-747.	3.6	6
21	The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD). <i>Metabolites</i> , 2019, 9, 25.	1.3	7
22	Reply to: "It takes two eyes to see in depth". <i>Journal of Hepatology</i> , 2019, 70, 791-793.	1.8	2
23	Low molecular weight heparin does not increase bleeding and mortality post-endoscopic variceal band ligation in cirrhotic patients. <i>Liver International</i> , 2018, 38, 1253-1262.	1.9	35
24	Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. <i>Cell Death and Disease</i> , 2018, 9, 87.	2.7	62
25	Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis. <i>Journal of Hepatology</i> , 2018, 68, 949-958.	1.8	108
26	Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals. <i>Hepatology</i> , 2018, 68, 1010-1024.	3.6	106
27	Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1153-1162.e7.	2.4	90
28	Obese zebrafish: A small fish for a major human health condition. <i>Animal Models and Experimental Medicine</i> , 2018, 1, 255-265.	1.3	28
29	Reply to: "Relationship of hyperdynamic circulation and cardiodynamic states in cirrhosis". <i>Journal of Hepatology</i> , 2018, 69, 748-749.	1.8	0
30	The Role of Anticoagulation in Treating Portal Hypertension. <i>Current Hepatology Reports</i> , 2018, 17, 200-208.	0.4	15
31	Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives. <i>Metabolites</i> , 2018, 8, 17.	1.3	36
32	Validating, deconstructing and refining Baveno criteria for ruling out high-risk varices in patients with compensated cirrhosis. <i>Liver International</i> , 2017, 37, 1177-1183.	1.9	97
33	Microenvironment inflammatory infiltrate drives growth speed and outcome of hepatocellular carcinoma: a prospective clinical study. <i>Cell Death and Disease</i> , 2017, 8, e3017-e3017.	2.7	45
34	Consensus conference on TIPS management: Techniques, indications, contraindications. <i>Digestive and Liver Disease</i> , 2017, 49, 121-137.	0.4	111
35	Low Molecular Weight Heparin (LMWH) treatment does not increase the risk of bleeding after prophylactic endoscopic variceal band ligation in patients with cirrhosis. <i>Digestive and Liver Disease</i> , 2016, 48, e21.	0.4	0
36	Neovascularization-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. <i>Gut</i> , 2016, 65, 861-869.	6.1	207

#	ARTICLE	IF	CITATIONS
37	Complete resolution of non-necrotizing lung granuloma and pyoderma gangrenosum after restorative proctocolectomy in a woman with severe ulcerative colitis and cytomegalovirus infection. <i>Clinical Case Reports (discontinued)</i> , 2016, 4, 195-202.	0.2	4
38	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. <i>Digestive and Liver Disease</i> , 2016, 48, 455-467.	0.4	57
39	Thrombophilic genetic risk factors for liver fibrosis: To screen or not to screen?. <i>Journal of Hepatology</i> , 2015, 63, 1311-1313.	1.8	2
40	Paradoxical embolization in TIPS: take a closer look to the heart. <i>Annals of Hepatology</i> , 2015, 14, 127-131.	0.6	4
41	The <i>cl2/dro1/ccdc80</i> null mice develop thyroid and ovarian neoplasias. <i>Cancer Letters</i> , 2015, 357, 535-541.	3.2	13
42	Prothrombotic genetic risk factors are associated with an increased risk of liver fibrosis in the general population. <i>Journal of Hepatology</i> , 2015, 63, 1459-1465.	1.8	31
43	The Coiled-Coil Domain Containing 80 (<i>ccdc80</i>) Gene Regulates <i>gadd45²</i> Expression in the Developing Somites of Zebrafish as a New Player of the <i>Hedgehog</i> Pathway. <i>Journal of Cellular Physiology</i> , 2015, 230, 821-830.	2.0	6
44	P316 Expression and functional role of <i>Ccdc80</i> in developing heart and in cardiomyopathies.. <i>Cardiovascular Research</i> , 2014, 103, S57.4-S58.	1.8	1
45	Unusual association between Budd-Chiari syndrome secondary to antiphospholipid syndrome and relapsing polychondritis: a case report and review of the literature. <i>Clinical Rheumatology</i> , 2013, 32, 905-907.	1.0	2
46	Tumor Suppressor Role of the <i>CL2/DRO1/CCDC80</i> Gene in Thyroid Carcinogenesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2834-2843.	1.8	33
47	Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: A case-control study. <i>Liver Transplantation</i> , 2013, 19, 450-456.	1.3	8
48	Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis. <i>Gastroenterology</i> , 2012, 143, 1253-1260.e4.	0.6	604
49	<i>ccdc80-11</i> Is Involved in Axon Pathfinding of Zebrafish Motoneurons. <i>PLoS ONE</i> , 2012, 7, e31851.	1.1	11
50	30 Days of Continuous Olanzapine Infusion Determines Energy Imbalance, Glucose Intolerance, Insulin Resistance, and Dyslipidemia in Mice. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 576-583.	0.7	41
51	Pathophysiology of portal hypertension and variceal bleeding. , 2009, , 137-148.		0
52	Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors. <i>Oncogene</i> , 2005, 24, 1882-1894.	2.6	111
53	Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data. <i>Hepatology</i> , 2004, 39, 333-342.	3.6	198
54	Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. <i>Gut</i> , 2004, 53, 925-930.	6.1	490

#	ARTICLE	IF	CITATIONS
55	Natural history of chronic HBV carriers in northern Italy: Morbidity and mortality after 30 years. <i>Gastroenterology</i> , 2004, 127, 756-763.	0.6	232
56	Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells. <i>Oncogene</i> , 2003, 22, 1087-1097.	2.6	56
57	When and how to treat acute hepatitis C?. <i>Journal of Hepatology</i> , 2003, 39, 1056-1062.	1.8	94
58	The effect of peginterferon alfa-2a (40 KD) on liver histology in chronic hepatitis C: A meta-analysis of individual patients data. <i>Journal of Hepatology</i> , 2003, 38, 33.	1.8	0
59	The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 15071-15076.	3.3	120
60	An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. <i>Cancer Research</i> , 2003, 63, 882-6.	0.4	49
61	Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. <i>Gut</i> , 2002, 51, 864-869.	6.1	26
62	Protection of Human Endothelial Cells From Oxidative Stress. <i>Circulation</i> , 2002, 105, 968-974.	1.6	89
63	Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Meta-Analysis of Randomized Controlled Trials. <i>Radiology</i> , 2002, 224, 47-54.	3.6	784
64	Re-treatment with interferon plus ribavirin of chronic hepatitis C nonresponders to interferon monotherapy: A meta-analysis of individual patient data. <i>Digestive and Liver Disease</i> , 2001, 33, A60.	0.4	0
65	Transarterial chemoembolization in patients with unresectable hepatocellular carcinoma: A meta-analysis of randomized controlled trials. <i>Digestive and Liver Disease</i> , 2001, 33, A113.	0.4	1
66	Effects of simvastatin treatment on sICAM-1 and sE-selectin levels in hypercholesterolemic subjects. <i>Atherosclerosis</i> , 2001, 155, 143-147.	0.4	34
67	Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection?. <i>Hepatology</i> , 2001, 33, 333-338.	3.6	248
68	MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 3969-3974.	3.3	239
69	Q-T interval prolongation in cirrhosis: Prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. <i>Hepatology</i> , 1998, 27, 28-34.	3.6	356
70	Outcome of liver disease and response to interferon treatment are not influenced by hepatitis B virus core gene variability in children with chronic type B hepatitis. <i>Journal of Hepatology</i> , 1997, 26, 765-770.	1.8	20